Characteristics | Non-NAFLD | NAFLD | P value |
---|---|---|---|
Patient characteristics | |||
Patients, n | 361 | 118 | |
Gender, n (%) | 0.064 | ||
Male | 310 (64.7%) | 109(22.8%) | |
Female | 51 (10.6%) | 9 (1.9%) | |
Age, No. (%) | 0.780 | ||
< 65 | 195 (40.7%) | 62 (12.9%) | |
≥ 65 | 166 (34.7%) | 56 (11.7%) | |
Body mass index (kg/m2)*, n (%) | < 0.001 | ||
≤ Median | 308 (64.3%) | 83 (17.3%) | |
> Median | 53 (11.1%) | 35 (7.3%) | |
ECOG performance status | 0.983 | ||
0 | 135 (28.2%) | 44 (9.2%) | |
≥ 1 | 226 (47.2%) | 74 (15.4%) | |
Diabetes, n (%) | 31 (6.5%) | 14 (2.9%) | 0.289 |
Hypertension, n (%) | 110 (23%) | 42 (8.8%) | 0.299 |
Smoking, n (%) | 190 (39.7%) | 70 (14.6%) | 0.205 |
Hyperlipidemia, n (%) | 109 (22.8%) | 39 (8.1%) | 0.560 |
Hemoglobin (g/L), mean (SD) | 123.7 (16.2) | 124.4 (16.4) | 0.674 |
Blood urea nitrogen (mmol/L), mean (SD) | 5.3 (1.7) | 5.6 (1.9) | 0.105 |
Serum creatinine (umol/L), mean (SD) | 72.0 (14.7) | 73.0 (15.0) | 0.530 |
Total bilirubin (mg/dL), mean (SD) | 10.5 (4.8) | 12.8 (6.1) | < 0.001 |
Alanine aminotransferase (U/L), mean (SD) | 24.5 (28.3) | 27.78 (26.9) | 0.281 |
Aspartate aminotransferase (U/L), mean (SD) | 23.4 (14.9) | 26.4 (28.9) | 0.139 |
Alkaline phosphatase (U/L), mean (SD) | 100.7 (59.1) | 102.8 (49.4) | 0.733 |
γ-glutamyl transpeptadase (U/L), mean (SD) | 47.4 (68.4) | 58.0 (60.4) | 0.133 |
Albumin (g/L), mean (SD) | 38.6 (4.9) | 37.6 (4.5) | 0.058 |
Albumin/Globulin ratio, mean (SD) | 1.5 (1.2) | 1.3 (0.3) | 0.144 |
lactic dehydrogenase (U/L), mean (SD) | 236.9 (115.8) | 229.2 (95.8) | 0.516 |
Pathological types, n (%) | 0.540 | ||
adenocarcinoma | 169 (35.3%) | 50 (10.4%) | |
squamous carcinoma | 169 (35.3%) | 62 (12.9%) | |
other | 23 (4.8%) | 6 (1.3%) | |
Types of ICIs, n (%) | 0.727 | ||
PD-1 antibody | 333 (69.5%) | 110 (23%) | |
PD-L1 antibody | 28 (5.8%) | 8 (1.7%) | |
Stages, n (%) | 0.998 | ||
Stage III | 260 (54.3%) | 85 (17.7%) | |
Stage IV | 101 (21.1%) | 33 (6.9%) |